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Association between benzodiazepine 
prescriptions and potential risk factors of 
adverse drug reactions among elderly and 
very elderly: findings from Friuli Venezia 
Giulia region, Italy 
ABSTRACT 
Background: benzodiazepines (BDZs) highly increase the risk of adverse drug reactions (ADRs), especially in the 
elderly with certain medical conditions. 
Methods: point-prevalence study in December 2017; 2,456 patients ≥65 years were included from 14 regional 
public and private hospitals, 24 long-term chronic care facilities (LTCCFs) and 20 nursing homes (NHs). Data 
regarded BDZ prescriptions and comorbidities, co-prescriptions, or concurrent diseases, which could increase the 
risk of ADRs in BDZ users. Univariate and multivariate logistic regression analyses were used to assess associations 
between ADRs in BDZ users vs. non-users, as well as within users.
Results: 671 patients were prescribed BDZ, whose half were in NHs. Being prescribed 10 or more drugs was twice 
more common among BDZ users compared to non-users. BDZs were prescribed for long-term to 80% of patients in 
NHs, while proportions were halved in hospitals and LTCCFs. In the analyses within BDZ users, patients in NHs and 
LTCCFs were at higher risk of dementia and concurrent use of opioid analgesic and antipsychotics compared to 
hospitalized patients. 
Conclusions: the use of BDZs in older patients is common in FVG. A great extent of comorbidities and concurrent 
medications at higher risk of ADRs was found. Analyses in different healthcare settings can allow to drive evidence-
based interventions in order to discourage the use of BDZs and monitor the raise of ADRs. 
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INTRODUCTION
Benzodiazepines (BDZs) have been well established 
as one of the most prescribed drug classes worldwide 
[1-7], although available data on the use of BDZ in 
the “real-world” showed a high variation, mainly due to 
different methods to assess BDZ use [8]. Findings based on 
national registers of prescriptions indicated a prevalence 
of BDZ varying from 4-5% [6,4], to 12-14% [9,1]. 
Further, BDZ use has been observed to increase with age 
[1,10,8,3,4,11,6,9]. Nonetheless, BDZs have been 
indicated to highly increase the risk of several adverse 
drug reactions (ADRs), if used in patients with certain 
medical conditions, such as disorders increasing the risk of 
respiratory insufficiency and the risk of falls and fractures, 
liver diseases, dementia and myasthenia gravis [1,12-15]. 
Concurrent use of certain medications, such as opioid 
analgesic, barbiturates, drugs depressing the central 
nervous system (CNS) or active on CNS further increases 
ADRs risk [1]. The elderly using BDZs were observed to 
be at the highest risk of developing ADRs, given those 
comorbidities and concurrent drug use [1,10,13,16,7,2]. 
According to Beers criteria [17], strong recommendation 
to totally avoid BDZs and hypnotics in the elderly has 
been given, particularly in case of delirium, dementia and 
history of falls and fractures. Minimizing the use of CNS 
drugs and avoid the concurrent use of three or more drugs 
active on CNS has been also strongly recommended [17]. 
Furthermore, long-term use of BDZs has been indicated to 
be particularly harmful in older patients, albeit it has been 
found to be more common in the elderly than in other ages 
[10,18,4,5,7]. Despite these warnings, however, few 
research assessed the extent of potential ADRs in older 
users of BDZs [1]. 
However, the amount of data with regard to 
inappropriate BDZ prescriptions is scarce [8]. Italy is 
sharing with many countries this issue, since BDZ are not 
included in the medications reimbursed by the National 
Health System (NHS), and, thus, are not recorded 
in national registers of prescriptions [19,20]. To our 
knowledge, further, no studies assessed the use of BDZs 
comparing different healthcare settings. This seems striking 
instead, since a detailed analysis of prescriptions’ pattern 
at different healthcare levels can be a first step for facing 
inappropriate prescriptions of BDZs and the potential onset 
of ADRs. A previous study based on a survey administered 
in Friuli Venezia Giulia (FVG) region, in fact, demonstrated 
that BDZs were ranking among the ten most frequently 
prescribed drugs and accounted for the majority of 
potential inappropriate prescriptions in regional hospitals, 
long-term chronic care facilities (LTCCFs) and primary 
care [21]. Elderly from the region were also likely to 
polypharmacy and potentially inappropriate prescriptions, 
in particular in hospitals and LTCCFs compared to 
community setting [21]. Another study from FVG found 
that BDZs were prescribed to 95% of older patients by 
a sample of General Practitioners (GPs) [19]. This study 
also observed that indications for BDZ prescriptions were 
in two-third of cases for psychiatric disorders, mainly for 
depressive and anxiety disorders [19]. 
The aim of this study was, thus, to assess the 
occurrence of BDZ prescriptions and their association with 
potential risk factors inducing ADRs among the elderly and 
very elderly patients in three different healthcare settings of 
Region Friuli Venezia Giulia (FVG).
METHODS
Study design and population
This is a point-prevalence study of BDZs and other 
drug prescriptions, carried out in three health-care settings 
in the FVG region from 11th December 2017 to 24th 
December 2017: all 14 regional public and private 
hospitals, 24 LTCCFs and 20 nursing homes (NHs). 
The eligible study sample were the elderly (aged from 
65 to 79 years) and the very elderly (aged more than 79 
years) who were taking at least one medication at the time 
of the survey, according to selection criteria listed below. 
Among them, we selected a sub-sample of BDZ users, who 
were dispensed at least one BDZ. 
Selection criteria were differently defined according 
to the health care setting. Regarding the hospital setting, 
patients were surveyed at the time of discharge from 
hospital. It involved all patients who were discharged 
during fourteen consecutive working days from the wards 
of internal medicine, geriatrics, cardiology, and neurology, 
patients that died during the hospitalization were excluded. 
Regarding LTCCFs, 50% of the residents were involved in 
the survey and they were randomly selected among the 
24 out of 90 regional LTCCFs which joined the study. 
Regarding NH, 10% of the residents were involved in the 
survey and they were randomly selected among the 20 out 
of 90 regional NH which joined the study. 
Recruitment of patients started simultaneously in the 
three settings. Nonetheless, we prevented the chance of 
being double-included in case of transfer from hospital 
to LTCCFs or NH carrying out the survey in these setting 
considering only residents that were present in the first day 
of survey.
Data on diagnoses and drug prescriptions were 
retrieved from discharge letters among hospitalized 
patients, whereas medical records were used regarding 
LTCCFs and NH. All data were centralized and then 
analysed at the FVG Regional ‘Safety Care’ Group, based 
in Udine, Italy. 
All data were managed confidentiality, patient 
identifiers were anonymous at the level of database and 
analysis; the surveys were included in the yearly goals for 
hospital chief executive officers (CEOs) as a part of the 
RHS program for the ‘safe-care network’ regional team.
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Diagnoses
Several selected patients’ diseases available at the 
time of the survey were registered. Diseases were classified 
according to International Classification of Diseases, tenth 
revision (ICD-10).
Diagnoses which could increase the risk of ADRs in 
BDZ users were then selected (Table 1) [1,17]. 
Drug prescriptions
All prescriptions available at the time of the survey 
were reported. Medications were classified according to 
the Anatomical Therapeutic Chemical classification [22]. 
Topical medications, homeopathic, over-the counter, and/
or natural remedies were considered outside of the scope 
of the study and were excluded from this analysis. Likewise, 
antineoplastic drugs were excluded from the analysis, as 
it is likely that these drugs are usually prescribed by 
oncologists in different specific wards.
Prescription attitude was defined as normal when <5 
drugs were co-prescribed, as polypharmacy when 5 to 
9 drugs were co-prescribed, and as hyper-polypharmacy 
when 10 or more drugs were co-prescribed.
Individuals having received at least one BDZ were 
then selected. Different BDZ medications were classified 
in two groups, according to the duration of action [17], 
as follows:
• Short and intermediate acting: oxazepam 
(N05BA04), alprazolam (N05BA12),  
etizolam (N05BA19), lorazepam (N05BA06), 
bromazepam (N05BA08), brotizolam 
(N05CD09), lormetazepam (N05CD06), 
estazolam (N05CD04), triazolam (N05CD05);
• Long acting: diazepam (N05BA01), ketazolam 
ICD-10 Codes ATC Codes
Comorbidities increasing the risk of ADRs in benzodiazepine user
Comorbidities at risk for adverse respiratory effects
COPD J41-J44 R03
Asthma J45-J46
Comorbidities that contraindicate benzodiazepine use
Myasthenia gravis N07AA
Liver disease K70-K77 A05
Dementia F00-F03 N06D
Comorbidities that increase the risk of falls and fracture
Osteoporosis and other disorders of bone density M05BA, M05BB
Gait and balance disorders
Parkinson disease G20 N04
Rheumatoid arthritis M05-M06





Antipsychotics N05A (N05AN excluded)
Centrally acting antihypertensives C02A
Non-benzodiazepine anxiolytics (idrossiazine) N05BB 






Other CNS active 
Muscle relaxants, centrally acting agents M03B
TABLE 1. Comorbidities and concurrent drug treatment which can increase the risk of adverse drug reactions (ADRs) in 
benzodiazepine users
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(N05BA10), prazepam (N05BA11), flurazepam 
(N05CD01), clonazepam (N03AE01), 
chlordesmethyldiazepam;
Midazolam (N05CD08) was excluded, as mainly 
used as anesthetics. 
Individuals using hypnotics (zolpidem; N05CF02) 
were included, as a separate group. 
Long-term use of BDZ was assessed if they were used 
for more than four weeks, as reported at the time of the 
survey in each healthcare setting, with regard to the last 
prescription assessed.
Assessment of increased risk of adverse drug reaction 
Comorbidities, co-prescriptions, or concurrent 
diseases and prescriptions, which can be considered to 
increase risk of adverse drug reactions (ADRs) in BDZ 
users, are summarized in Table 1. ADRs may regard 
different symptoms mainly related to depressant effect 
on CNS, such as respiratory depression, drowsiness, 
muscle weakness, sedation [1]. According to Beers 
criteria [17] and international literature [1], they regarded 
co-morbidities with diseases and drugs at higher risk of 
adverse respiratory effects, falls and fractures, general 
contraindication to BDZ (liver disorders, dementia and 
myasthenia gravis), concurrent use of drugs with depressant 
effect on respiratory system and CNS, as well as other 
drugs active on CNS. 
Statistical analysis
All variables were dichotomous or categorical and 
were tabulated into contingency tables and the chi-square 
statistic (χ2) for categorical data was used to test the 
differences between observed and expected frequencies. 
Univariate and multivariate logistic regression 
analyses were used to assess the associations between 
outcomes (use of BDZ vs. non-use of BDZ) and predictors 
(gender, age groups, number of prescribed drugs, setting 
and comorbidities and concurrent drug treatment which 
can increase the risk of adverse drug reactions (ADRs) 
associated to BDZ use). Multivariate logistic regression 
analyses were also applied within BDZ users to assess the 
association between outcomes (gender, age groups and 
setting) and predictors (comorbidities and concurrent drug 
treatment).
Crude and adjusted odds ratios (OR) and 95% 
confidence intervals (95% CI) were estimated from the 
logistic regression coefficients and their respective standard 
errors. A P-value (P) < 0.05 was set as the threshold for 
statistical significance.
Descriptive and inferential analyses were performed 
using the statistical software Stata/SE (version 15.1).
RESULTS
Characteristics of patients prescribed and not 
prescribed benzodiazepines 














Males 575 (50.4) 103 (39.6) 91 (23.8)
0.000
64 (36.0) 56 (31.3) 82 (26.1)
0.170
Females 561 (49.1) 154 (59.2) 290 (75.7) 114 (64.0) 123 (68.7) 231 (73.6)
Missing 6 (0.5) 3 (1.2) 2 (0.5) 0 0 1 (0.3)
Age (years)
Elderly 
(65-79) 454 (39.8) 79 (30.4) 78 (20.4)
0.000




688 (60.2) 181 (69.6) 305 (79.6) 103 (57.9) 94 (52.5) 234 (74.5)
N of prescribed drugs
1-4 306 (26.8) 55 (21.2) 80 (20.9)
0.022
26 (14.6) 15 (8.3) 26 (8.2)
0.0215-9 679 (59.5) 155 (59.6) 236 (61.6) 103 (57.9) 105 (58.7) 163 (51.9)
≥10 157 (13.7) 50 (19.2) 67 (17.5) 49 (27.5) 59 (33.0) 125 (39.8)
H hospital; LTCCF long-term chronic care facilities; NH nursing home; N numbers
P-value was obtained by chi-square test and was used to assess whether proportions of individuals not prescribed BDZ or prescribed BDZ, 
respectively, were differently distributed in the three settings in relation to genders, age groups and number of drugs prescribed
TABLE 2. Patient’s characteristics
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Overall, 2,456 patients were included, whose 
671 (27.3%) were prescribed at least one BDZ. In all 
settings, beside BDZ prescription, patients were more 
likely to be females, aged over 80 years old and being 
prescribed five to nine drugs (Table 2). Interestingly, hyper-
polypharmacy was almost twice more common among 
BDZ users compared to non-users in all different settings, 
with almost 40% of BDZ users in NHs being prescribed 
10 or more drugs. 
Nearly half of BDZ users were in NHs, (Table 2). 
The majority (64.0%) of subjects who were not dispensed 
BDZs were hospitalized, whilst BDZ users were only 26%. 
Patients in LTCCFs were more likely to be not prescribed 
BDZs (59.2%), than prescribed (40.8%).
When BDZ users were compared with non-BDZ users 
in the multivariate regression analysis (Table 3), BDZ users 
were 1.5 times more likely to be females and 4 times more 
likely of being in outpatient services (LTCCF and NH) than 
in hospital. BDZ users were also at higher risk of being 
prescribed from 5 to 10 and more drugs, compared to 
patients being prescribed up to 4 drugs 
Information on benzodiazepine use
As summarized in Table 4, short-intermediate acting 
BDZs were the most used (N = 431; 64.2%), and they 
significantly differed between settings, albeit almost 70% 
of patients in NHs and in hospital were prescribed 
these drugs. Among different BDZ active principles, 
chlordesmethyldiazepam and lorazepam were the most 
used, representing almost half of total prescriptions in all 
settings. Interestingly, almost 80% of patients in NHs were 
prescribed BDZs for more than 4 weeks, while proportions 
were 37% in hospitals and 24.5% in LTCCFs. 
Almost 10% of patients (N = 62) were dispensed two 
BDZs simultaneously, while 4 patients were dispensed three. 
Adverse drug reactions in benzodiazepine users
In the multivariate regression analysis, being prescribed 
BDZs was significantly associated only to Parkinson 
disease, whilst the use of antipsychotics was negatively 
associated to BDZ use (Table 3).
When the analyses were restricted to BDZ users (Table 
5), women and subjects aged 80 years and more were 
at higher risk of dementia and osteoporosis compared to 
men and younger than 80 years, respectively. Patients in 
NHs were at higher risk of dementia, while they were at 
lower risk of COPD compared to hospital patients. On the 
other hand, patients in LTCCFs were at lower risk of liver 
diseases and concurrent use of sedative antidepressants. 
Patients in LTCCFs and in NHs were more likely to 
concurrent use antipsychotics compared to hospitalized 
patients. 
DISCUSSION
The use of benzodiazepines
Our study highlighted that more than 60% of BDZs in 
older patients were prescribed to women and subjects with 
80 years and more, consistent with international literature 
[1,8,11,6,13,9,23,16]. Old women were at 1.5 higher 
risk of being prescribed BDZs, as observed in a previous 
Swedish study [16]. Among patients not prescribed BDZs, 
however, the majority were also women and very elderly, 
indicating a frequently observed drugs’ dispensation 
pattern [24,20,21]. Moreover, BDZ users were more 
exposed to polypharmacy than non-BDZ users. This can be 
related with a poorer health status among BDZ users [25], 
which can be associated with a higher use of medical 
care [12] and consequent increase in drugs’ prescription. 
One of main findings of the present study was that 
BDZs were four times more likely to be prescribed in 
outpatient healthcare settings compared to hospital. Almost 
half of patients in NHs, for instance, had been prescribed 
at least one BDZ, which was much greater than a study 
from United States, where BDZs were dispensed to only 
1.7% of NH residents [26]. Conversely, our findings of 
BDZ prescription to 13% of inpatients is somewhat in line 
with other hospital studies, which indicated that new BDZs 
were dispensed in 2.2% to 24% of admissions [8]. Most 
of patients in all settings were dispensed short-intermediate 
acting BDZs, consistent with other studies [10,6,13,19]. 
However, we observed that almost 80% of patients in 
NHs were long-term BDZ users, compared to more than 
half lower proportions in LTCCFs and hospitals. Although 
long-term use of BDZ is very common [8], particularly in 
the elderly [10,18,4,5], whether this was so prominent 
in NHs might be related to different factors. In FVG, most 
of prescriptions at the primary care level, including NHs, 
are filled by GPs [27], and GPs had been previously 
observed to dispense BDZ for long time to older patients 
[19]. On the other hand, BDZs are usually prescribed to 
inpatients by specialized doctors, who are less prone to 
dispensing these drugs [28]. Similarly, specialized doctors 
are also the main prescribers at LTCCFs. Other reasons 
for the greatest long-term use of BDZs in NHs might be 
related to higher competitive demands on doctor time to 
other medical needs, or minor access to other therapeutic 
alternatives [6]. 
To date, a strength of our study is that provided 
a comparison on BDZs prescriptions’ patterns in three 
different settings, which is crucial for guiding policies 
aimed to enhance safer drug use and patients’ safety 
[20]. In contrast, research on BDZ is usually based on 
a specific healthcare setting [7]. Our findings indicate 
that interventions should be addressed primarily to 
NHs and secondly to LTCCFs and hospital, according 
to the extent of BDZ prescriptions. Several studies 
had explored effective interventions to reduce the use 
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of BDZs in older people [29,7,30]. They regarded 
reduction of BDZs using combined patient-centered 
care [7], clinical education and medication review 
[29], as well as minimal strategies, such as clinical 
reassessment of benefits and harms [30]. Recently, 
FVG healthcare system adopted a deprescribing 
algorithm for BDZ and hypnotics, based on Pottie and 




(n = 671) Univariate Multivariate
Variables N (%) N (%) P OR 95% CI P OR 95% CI
Gender b
Males 769 (43.1) 202 (30.1) 1.0 - 1.0 -
Females 1005 (56.3) 468 (69.7) 0.000 1.773 1.466-2.143 0.000 1.504 1.213-1.866
Age (years)
Elderly (65-79) 611 (34.2) 240 (35.8) 1.0 - - -
Very elderly (≥80) 1174 (65.8) 431 (64.2) 0.475 0.935 0.776-1.125 - -
N of prescribed drugs
1-4 441 (24.7%) 67 (10.0%) 1.0 - 1.0 -
5-9 1070 (59.9%) 371 (55.3%) 0.000 2.282 1.720-3.028 0.000 2.059 1.530-2.771
≥10 274 (15.4%) 233 (34.%) 0.000 5.597 4.102-7.637 0.000 4.535 3.236-6.356
Setting
Hospital 1142 (64.0) 178 (26.5) 1.0 - 1.0 -
LTCCF 260 (14.6) 179 (26.7) 0.000 4.417 3.449-5.656 0.000 4.072 3.142-5.278
NH 383 (21.4) 314 (46.8) 0.000 5.260 4.233-6.536 0.000 4.498 3.531-5.729
Comorbidities
COPD 341 (19.1) 111 (16.5) 0.145 0.839 0.663-1.062 - -
Asthma 14 (0.8) 4 (0.6) 0.627 0.759 0.249-2.313 - -
Myasthenia gravis 2 (0.1) 1 (0.1) 0.816 1.331 0.120-14.698 - -
Liver disease 161 (9.0) 70 (10.4) 0.286 1.175 0.874-1.579 - -
Dementia 411 (23.0) 163 (24.3) 0.509 1.073 0.871-1.321 - -
Osteoporosis 387 (21.7) 192 (28.6) 0.000 1.448 1.183-1.772 0.928 1.011 0.804-1.270
Parkinson disease 91 (5.1) 66 (9.8) 0.000 2.031 1.460-2.825 0.000 1.938 1.339-2.806
Rheumatoid arthritis 76 (4.3) 20 (3.0) 0.148 0.691 0.419-1.140 - -
Concurrent medications
Opioid analgesics 214 (12.0) 144 (21.5) 0.000 2.006 1.589-2.533 0.112 1.239 0.951-1.612
Barbiturates 37 (2.1) 16 (2.4) 0.636 1.154 0.638-2.089 - -
Antipsychotics 432 (24.2) 218 (32.5) 0.000 1.507 1.241-1.831 0.037 0.786 0.627-0.986
CA antihypertensives 22 (1.2) 7 (1.0) 0.699 0.845 0.359-1.987 - -
Idrossiazine 6 (0.3) 3 (0.4) 0.686 1.332 0.332-5.339 - -
Sedative AD c 107 (6.0) 69 (10.3) 0.000 1.797 1.310-2.467 0.621 1.092 0.769-1.551
CA Muscle relaxants 10 (0.6) 10 (1.5) 0.028 2.685 1.113-6.481 0.232 1.795 0.687-4.691
N numbers; BDZ benzodiazepine; OR odds ratio; CI confidence interval; COPD Chronic obstructive pulmonary disease; CA central acting; AD 
antidepressants
a Individuals who were not prescribed BDZ were used as reference category (OR =1)
b Gender is missing in 12 patients
c Agomelatine, amitriptyline, doxepin, mianserin, mirtazapine, trimipramine, trazodone
TABLE 3. Comparison between non use of BDZ and use of BDZ according to patient’s characteristics, comorbidities and concurrent 
drug treatment which can increase the risk of adverse drug reactions (ADRs) at univariate and multivariate logistic regression. . 
Significant Odds ratio and 95% Confidence Intervals were highlighted in bold. 
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The extent of factors which can induce adverse drug 
reactions 
Potential factors inducing ADRs were analysed using 
two parameters: first, we compare BDZ users and non-
users with regard to these factors; second, we assess the 
extent of potential ADRs among BDZ users in different 
healthcare settings. This is a strength of the present study, 
although previous research had clearly identified the risk 
of developing ADRs under certain comorbidities and 
concurrent drug use [1,15,12-14]. 
In contrast with other studies [12,11], which 
demonstrated a higher degree of medical comorbidities 
among BDZ users, in our study BDZs were positively 
associated only to Parkinson disorder when compared to 
non-users. This might be related to the high association of 
anxiety disorders to Parkinson and the paucity of effective 
treatments [32], which may lead to the choice of BDZs, 
since they can be used also on demand [33]. Conversely, 
antipsychotics were negatively associated to BDZ use in 
the multivariate analysis. This can indicate a competitive 
treatment choice between antipsychotics and BDZs in the 
elderly [18], when taken into account several comorbidities 
and concurrent drug use. Nonetheless, proportions of 
comorbidities and concurrent medications at increased 
risk of ARDs among BDZ users were in general higher 
than those observed in other studies [1,9]. Our findings, 
however, are based on healthcare settings, while the 
other two studies [1,9] were population-based, with the 
consequence of a possible drop in comorbid disorders and 
concurrent medications. In any case, our study observed 
that one-quarter of BDZ users were patients with dementia, 
which was almost three times higher than previous finding 
from Israel [9]. Further, BDZ users in NHs were at almost 
three times increased risk of dementia compared to hospital. 
Since a recent study demonstrated a strong association 
between long-term exposure to BDZs and risk of Alzheimer 
disease [15], this seems of particular concern. 
Moreover, it was noteworthy that antipsychotics, 
which could increase the risk of ADRs in BDZ users, were 
significantly associated to NH patients. This confirms the 
need of addressing interventions to discourage the use of 
BDZs and monitoring the potential onset of ADRs, primarily 
among patients in NHs.
Limitations
Several limitations should be acknowledged for the 
correct interpretation of our results. Firstly, the voluntary 
basis of the adherence to the study by NHs and LTCCFs 
may represent a bias. Secondly, only patients who were 
taking at least one drug during the two-weeks study’s 
recruitment were included. This may have biased our 
results, since patients included had probably more severe 
health conditions. Nonetheless, the study was carried 
out not to analyse the prevalence of citizens that took 
medications but to identify the major concerns about drugs 
H (n =178)a LTCCF (n =179)a NH (n =314)a
Benzodiazepines N (%) % >4 w b N (%) % >4 w b N (%) % >4 w b P
Short-intermediate acting 120 (67.4) 44.2 100 (55.9) 23.0 211 (67.2) 75.4 0.24
alprazolam 25 (14.0) 44.0 17 (9.5) 5.9 21 (6.7) 71.4 0.027
bromazepam 21 (11.8) 23.8 26 (14.5) 30.8 35 (11.1) 77.1 0.53
lorazepam 38 (21.3) 55.3 28 (15.6) 25.0 85 (27.1) 78.8 0.01
lormetazepam 10 (5.6) 60.0 18 (10.1) 33.3 39 (12.4) 64.1 0.05
triazolam 24 (13.5) 41.7 12 (6.7) 16.7 42 (13.4) 80.9 0.06
other c 5 (2.8) 40.0 3 (1.7) - 7 (2.2) 85.7 0.77
Long acting 50 (28.1) 30.0 65 (36.3) 26.1 101 (32.2) 85.1 n.s.
diazepam 9 (5.1) 22.2 8 (4.5) 25.0 18 (5.7) 77.8 0.25
chlordesmethyldiazepam 34 (19.1) 32.3 54 (30.2) 27.8 71 (22.6) 88.7 0.04
other d 7 (3.9) 28.6 4 (2.2) - 23 (7.3) 78.3 0.03
Hypnotics (zolpidem) 13 (7.3) 7.7 22 (12.3) 4.5 22 (7.0) 40.9 0.10
H hospital; LTCCF long-term chronic care facilities; NH nursing home; N numbers; w weeks; on d. on demand; 
P-value was obtained by chi-square test and was used to assess whether proportions of BDZ type were differently distributed in the three settings
ª Numbers are lower than the sum of patients in different benzodiazepine and hypnotic drugs, due to co-prescriptions
b Percentages were calculated on the number of individuals prescribed with each type of BDZ
c Brotizolam, etizolam, estazolam, oxazepam
d Clonazepam, flurazepam, prazepam, ketazolam
TABLE 4. Distribution of benzodiazepines (BDZ) prescriptions in different settings. Percentages of BDZ used for more than four weeks 
were calculated on the number of individuals prescribed with each type of BDZ.
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management. [21]. Thirdly, the territorial area where the 
study was performed was limited, with the consequence 
of a low number of patients in certain subgroups, which 
hindered more detailed analyzes and the generalizability 
of the conclusions. Fourthly, no information on the volume, 
the dosage and the number of prescriptions of BDZs were 
available. Fifthly the reason for prescribing BDZs was 
missing. However, indication is often not well documented 
in other research [6,9], and BDZs are often prescribed 
“off-label” [8], which can increase the lack of reliable 
data on indications. Moreover, diagnoses derived from 
both medical records and discharge letters which may 
have been differently filled. They were also clinical and 
not validated, as acknowledged in other register studies 
from the Region [34,35]. Sixthly, long-term use was 
assessed when BDZs were dispensed for more than four 
weeks, according to international recommendations [5]. 
However, we had no information on the exact length 
of each BDZ dispensation, albeit it is likely that most of 
long-term prescriptions were much longer than one month, 
particularly in NHs where people are resident and data 
about drugs therapy can be available for a long period 
of time. A recent study, in fact, suggested to define long-
term BDZ use when BDZs are prescribed continuously for 
six months and more during one year, in order to obtain 
data closer to real-world use [5]. Finally, the extent of 
factors inducing ADRs in BDZ users is not complete and 
consequent risk estimation may had been conservative, as 
previously highlighted in other studies [1,13]. A possible 
underestimation of ADRs in BDZ users, for instance, would 
have happened in case of concurrent use of alcohol or 
illicit drugs [1,13].
CONCLUSIONS
The present study highlighted that BDZs were 
broadly used in older patients in different healthcare 
Gender a Age b Setting c
Female Very elderly (≥80) LTCCF NH
Variables OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Comorbidities
COPD 0.80 0.52-1.29 1.06 0.66-1.65 0.60 0.35-1.03 0.9 0.30-0.78
Asthma - - 0.83 0.08-8.41 - - 1.52 0.15-15.28
Myasthenia gravis - - - - - - - -
Liver disease 0.75 0.42-1.37 0.36 0.20-0.65 0.45 0.21-0.98 0.71 0.38-1.36
Dementia 1.81 1.16-2.83 1.74 1.14-2.66 1.15 0.64-2.03 2.60 1.60-4.14
Osteoporosis 3.12 1.96-4.96 1.58 1.06-2.35 1.62 0.99-2.67 1.35 0.86-2.12
Gait and balance 
disorders d 1.18 0.70-1.99 0.24 0.14-0.40 0.54 0.27-1.08 1.30 0.74-2.29
Concurrent medications
Opioid analgesics 1.47 0.78-2.77 0.66 0.370-1.216 1.51 0.68-3.34 1.91 0.93-3.91
Barbiturates 0.84 0.29-2.39 0.22 0.07-0.64 0.30 0.03-2.89 3.39 0.93-12.33
Antipsychotics 0.79 0.52-1.11 0.58 0.40-0.84 2.00 1.17-3.40 4.93 3.06-7.93
CA 
antihypertensives 1.12 0.21-6.17 0.68 0.14-3.40 1.92 0.18-21.59 2.41 0.26-22.16
Idrossiazine 0.21 0.13-3.62 - - - - - -
Sedative AD e 0.83 0.47-1.48 0.81 0.46-1.43 0.34 0.14-0.80 1.00 0.55-1.77
CA Muscle 
relaxants 0.34 0.07-1.71 0.40 0.07-1.93 0.22 0.02-1.90 - -
N numbers; LTCCF long-term chronic care facilities; NH nursing home; OR odds ratio; CI confidence interval; COPD Chronic obstructive pulmonary 
disease; CA central acting; AD antidepressants
a Males were used as reference category (OR =1)
b Elderly (65-79 years) was used as reference category (OR =1)
c Hospital was used as reference category (OR =1)
d Parkinson disease and Rheumatoid Arthritis
e Agomelatine, amitriptyline, doxepin, mianserin, mirtazapine, trimipramine, trazodone
TABLE 5. Multivariate logistic regression for comorbidities and concurrent drug treatment which can increase the risk of adverse drug 
reactions (ADRs) in benzodiazepine users, according to gender, age groups and settings. Mutually adjusted odds ratios (OR) and 
95% confidence intervals (95% CI) are estimated by means of logistic regression analysis. Significant ORs are highlighted in bold. 
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settings in FVG, particularly among women and very 
elderly. Our findings are consistent with population-based 
studies [1,8,11,6,13,9,23,16], although international 
recommendations claim to avoid BDZ use among the 
elderly [17]. Moreover, we found that some comorbidities 
and concurrent medications, which can highly increase the 
risk of ARDs, were more likely among BDZ users, when 
comparing different settings. In certain conditions such as 
dementia, where BDZs are strongly contraindicated, this 
is a reason of concern[15,17]. Since no previous studies 
compared the use of BDZs among different healthcare 
settings, an original finding was the greatest degree of 
prescriptions among outpatients in NHs compared to 
hospital. This is of major interest to drive focused policies 
to enhance safer drug use and patients’ safety [20]. 
Notwithstanding the limitations, our findings indicate that 
evidence-based interventions [29,7,30,31] should be 
addressed to discourage the use of BDZs and monitor 
the raise of ADRs. Future research would benefit from the 
monitoring of BDZ prescription trends using longitudinal 
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